Print
|
Close
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Active:
Yes
Cancer Type:
Prostate Cancer
NCT ID:
NCT06516510
Trial Phases:
Protocol IDs:
BET-PSMA-001 (primary)
NCI-2024-09547
Eligibility:
60 Years and older, Male
Study Type:
Other
Study Sponsor:
Blue Earth Therapeutics Ltd
NCI Full Details:
http://clinicaltrials.gov/show/NCT06516510
Summary
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of
lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in
patients with non-curative metastatic prostate cancer
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.